Abstract Body

Early ART improves disease outcomes in infected children but does not eliminate latent HIV reservoirs. Studies in a small subset of perinatally infected children who developed HIV-specific antibody responses and remained virus free when ART was interrupted, suggested that autologous antibody responses maybe important for sustained viral control and lack of virus rebound. However, kinetics of HIV-specific antibody responses and their impact on virus rebound in the setting of postnatal HIV transmission is unclear. We used an established infant rhesus macaque (RM) SHIV infection model with delayed ART to define the kinetics, specificity, breadth, and antiviral functions of HIV-specific antibodies in the setting of postnatal HIV infection.

10 infant RMs were orally challenged with SHIV.C.CH505 375H dCT and daily triple ART initiated at 8wpi. ART was interrupted after 52 weeks and virus rebound was monitored by viral RNA detection in infant plasma. Antibody development was assessed by binding to the autologous virus CH505 TF gp120 and MN gp41. HIV epitope and clade specificities were assessed using a multiplex luminex assay (BAMA). Plasma antibody neutralizing and non-neutralizing functions were evaluated at time points pre-ART, during ART, and ATI.

HIV envelope (Env) gp120- and gp41-specific antibodies were first detected at 4wpi and decline after ART initiation (8wpi). Yet, the antibody levels remained detectable throughout ART. Plasma Env-specific antibodies predominantly targeted the V3-loop, C5 region, and showed broad reactivity against heterologous HIV Envs. Plasma antibody at pre-ART, during ART, and post-ATI mediated robust ADCP activity against CH505 TF-gp120-coated beads but limited ADCC activity against SHIV-infected cells at similar time points. 5 of 10 infants developed autologous virus neutralization while on ART. Upon ATI, virus rebound was observed in all infants (range, 7-35 days) except 1 infant that developed highest level of autologous plasma neutralization. Pseudoviruses generated using rebound Envs were resistant to autologous plasma neutralization. Computational machine learning analyses identified autologous neutralization as strongest predictor of delayed virus rebound.

Development of autologous virus neutralizing antibody may delay time to virus rebound. This study underscores the importance to explore augmentation of autologous virus neutralization as a potential strategy to afford viral remission or cure in pediatric HIV.